Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0128 in metastatic castration-resistant prostate cancer
NCT02091531Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2014
- Primary completion
- Oct 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapanisertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Median Time on Treatment at 8 months. Started Mar 2014; status: completed.
02
Drugs
sapanisertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02091531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091531.